cas 2252403-82-8|| where to buy 7-Chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

Nom du produit:7-Chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

IUPAC Name:7-chloro-6-fluoro-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-1H,2H,3H,4H-pyrido[2,3-d]pyrimidine-2,4-dione

: CAS：2252403-82-8; Formule moléculaire：C16H14ClFN4O2; Pureté：95%+

Unité d'emballage	Stock disponible	Prix($)
CM337558-100g	in stock	ȤŸƚƚ
CM337558-500g	in stock	ƚȅœƴ
CM337558-1000g	in stock	Ȗœœœ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2252403-82-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2252403-82-8; Formule moléculaire:C16H14ClFN4O2; Point de fusion:-; Code SMILES:O=C1N(C2=C(C)C=CN=C2C(C)C)C3=NC(Cl)=C(F)C=C3C(N1)=O; Densité:

: Numéro de catalogue:CM337558; Poids moléculaire:348.76; Point d'ébullition:; N° Mdl:; Stockage:Keep in a tight container and store at abient temperature

: Sotorasib; Dec. 26, 2023, Amgen announced that the U.S. FDA has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS (sotorasib).
LUMAKRAS (sotorasib) is an oral, first-in-class therapy indicawithted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following at least one previous systemic therapy.
Sotorasib is the first approved targeted therapy for patients with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in NSCLC. The U.S. FDA granted the application for sotorasib orphan drug, fast track, priority review, and breakthrough therapy designations.